Idelalisib (CAL-101, GS-1101)

For research use only. Not for use in humans.

目录号：S2226 中文名称：艾代拉里斯，艾代拉利司

Idelalisib (CAL-101, GS-1101) Chemical Structure

CAS No. 870281-82-6

Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂，在无细胞试验中IC50为 2.5 nM；对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍，对p110δ的选择性是对 C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。Idelalisib 还可诱导自噬。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1279.19	现货
10mg	RMB 972.85	现货
50mg	RMB 3867.24	现货
200mg	RMB 10401.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Idelalisib (CAL-101, GS-1101)发表文献187篇：

Cell, 2020, S0092-8674(20)31394-5

PubMed: 33147445 ( click the link to review the publication )

Nat Mater, 2019, 18(8):892-904

PubMed: 31235902 ( click the link to review the publication )

Lancet Oncol, 2018, 19(4):486-496

PubMed: 29475723 ( click the link to review the publication )

Cell, 2018, 173(2):470-484

PubMed: 29551267 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):982-995

PubMed: 30503705 ( click the link to review the publication )

Nature, 2017, 8;546(7657):302-306.

PubMed: 28562582 ( click the link to review the publication )

Nature, 2017, 23;542(7642):489-493.

PubMed: 28199309 ( click the link to review the publication )

Nature, 2017, 552(7683):121-125

PubMed: 29143824 ( click the link to review the publication )

Nature, 2016, 539(7629):437-442

PubMed: 27642729 ( click the link to review the publication )

Nature, 2015, 22;517(7535):460-5.

PubMed: 25517094 ( click the link to review the publication )

Nature, 2015, 517(7535):460-5

PubMed: ( click the link to review the publication )

Cancer Discov, 2014, 4(9):1022-35

PubMed: 25082755 ( click the link to review the publication )

Nature, 2013, 25;496(7446):523-7.

PubMed: 23619696 ( click the link to review the publication )

J Exp Med, 2021, 218(2)e20200517

PubMed: 33075129 ( click the link to review the publication )

J Clin Invest, 2020, 19 pii: 134424

PubMed: 32191635 ( click the link to review the publication )

Nucleic Acids Res, 2020, 26;gkaa431

PubMed: 32453417 ( click the link to review the publication )

Mol-Ther, 2020, 6;28-5-:1263-1275

PubMed: 32145202 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1183-x

PubMed: 32034308 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):228

PubMed: 33115525 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2725

PubMed: 32977449 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01117-8

PubMed: 33082556 ( click the link to review the publication )

Br J Cancer, 2020, 18

PubMed: 32418995 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.0973.2019

PubMed: 33037136 ( click the link to review the publication )

Br J Haematol, 2020, 10.1111/bjh.17139

PubMed: 33216963 ( click the link to review the publication )
Cell Oncol (Dordr), 2020, 8

PubMed: 32382996 ( click the link to review the publication )

J Gerontol A Biol Sci Med Sci, 2020, glaa216

PubMed: 32877922 ( click the link to review the publication )

Mol Cancer Res, 2020, 11

PubMed: 32161139 ( click the link to review the publication )

J Cell Sci, 2020, 11 pii: jcs

PubMed: 32393599 ( click the link to review the publication )

Eur J Immunol, 2020, 8

PubMed: 32383488 ( click the link to review the publication )

Cancer Immunol Immunother, 2020, 69(4):501-512

PubMed: 31950225 ( click the link to review the publication )

Sci Rep, 2020, 1;10(1):8867

PubMed: 32483262 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Int J Biochem Cell Biol, 2020, 122:105734

PubMed: 32119989 ( click the link to review the publication )

Cell Biol Int, 2020, 10.1002/cbin.11322

PubMed: 32068318 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Turk J Haematol, 2020, 37(3):167-176

PubMed: 32160736 ( click the link to review the publication )

Iran J Pharm Res, 2020, 19(1):153-165

PubMed: 32922477 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:390

PubMed: 32817744 ( click the link to review the publication )

Blood Adv, 2020, 4(24):6106-6116

PubMed: 33351104 ( click the link to review the publication )

Blood Adv, 2020, 4(13):3072-3084

PubMed: 32634240 ( click the link to review the publication )

Data Brief, 2020, 32:106185

PubMed: 32904194 ( click the link to review the publication )

Viruses, 2020, 12(6):E652

PubMed: 32560319 ( click the link to review the publication )

Haematologica, 2020, 10.3324/haematol.2019.227215

PubMed: 31919082 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4382-4392

PubMed: 32926124 ( click the link to review the publication )

Arterioscler Thromb Vasc Biol, 2020, 40(1):86-102

PubMed: 31597445 ( click the link to review the publication )

Gastroenterology, 2019, 157(6):1615-1629

PubMed: 31446059 ( click the link to review the publication )

Blood, 2019, 134(21):1821-1831

PubMed: 31527074 ( click the link to review the publication )
Leukemia, 2019, 10.1038/s41375-019-0486-9

PubMed: 31148590 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0569-7

PubMed: 31471562 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2202

PubMed: 31831562 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1312-1324

PubMed: 30737788 ( click the link to review the publication )

Am J Transplant, 2019, 19(5):1305-1314

PubMed: 30549430 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31601046 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):20

PubMed: 30709367 ( click the link to review the publication )

Cell Death Dis, 2019,

PubMed: 31801949 ( click the link to review the publication )

Cell Biol Toxicol, 2019, 10.1007/s10565-019-09487-3

PubMed: 31522336 ( click the link to review the publication )

Epigenetics, 2019, 1-16

PubMed: 31216925 ( click the link to review the publication )

Cancer Sci, 2019, 110(3):997-1011

PubMed: 30618098 ( click the link to review the publication )

J Immunol, 2019, 202(5):1397-1405

PubMed: 30692213 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Lab Invest, 2019, 99(5):648-658

PubMed: 30679758 ( click the link to review the publication )

Front Microbiol, 2019,

PubMed: 32038504 ( click the link to review the publication )

Mar Drugs, 2019, 17(9)E526

PubMed: 31505769 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 381:114729

PubMed: 31445927 ( click the link to review the publication )

J Cell Biochem, 2019, 120(8):14004-14016

PubMed: 30957273 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 116:105615

PubMed: 31539632 ( click the link to review the publication )

Eur J Pharmacol, 2019, 842:89-98

PubMed: 30401630 ( click the link to review the publication )

Arch Pharm Res, 2019, 10.1007/s12272-019-01163-8

PubMed: 31161369 ( click the link to review the publication )

Iran J Pharm Res, 2019, 18(Suppl1):119-131

PubMed: 32802093 ( click the link to review the publication )

Blood Adv, 2019, 3(20):2920-2933

PubMed: 31648314 ( click the link to review the publication )
EMBO J, 2018, 37(11)

PubMed: 29669863 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129

PubMed: 29066507 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1103-1113

PubMed: 29246942 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3967-3980

PubMed: 29666304 ( click the link to review the publication )

Cancer Immunol Res, 2018, 6(10):1150-1160

PubMed: 30089638 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Cell Rep, 2018, 24(8):2155-2166

PubMed: 30134175 ( click the link to review the publication )

EBioMedicine, 2018, 31:217-225

PubMed: 29759484 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):935

PubMed: 30224718 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2091-2099

PubMed: 30045927 ( click the link to review the publication )

Br J Haematol, 2018, 182(5):654-669

PubMed: 29978459 ( click the link to review the publication )

Br J Haematol, 2018, 183(3):428-444

PubMed: 30125933 ( click the link to review the publication )

J Immunol, 2018, 201(2):406-416

PubMed: 29884706 ( click the link to review the publication )

J Cell Physiol, 2018, 233(8):6052-6066

PubMed: 29319168 ( click the link to review the publication )

Eur J Immunol, 2018, 48(11):1796-1809

PubMed: 30184252 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Eur J Haematol, 2018, 10.1111/ejh.13075

PubMed: 29617050 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29423101 ( click the link to review the publication )

JCI Insight, 2018, 3(11)

PubMed: 29875321 ( click the link to review the publication )

Oncotarget, 2018, 9(30):21166-21181

PubMed: 29765528 ( click the link to review the publication )

Oncotarget, 2018, 9(31):21820-21830

PubMed: 29774105 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9273-9284

PubMed: 29507689 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29565-29573

PubMed: 30038704 ( click the link to review the publication )

Oncotarget, 2018, 9(40):26019-26031

PubMed: 29899839 ( click the link to review the publication )
Blood, 2017, 5;129(1):88-99

PubMed: 27784673 ( click the link to review the publication )

Blood, 2017, 27;130(4):501-513

PubMed: 28533307 ( click the link to review the publication )

Blood, 2017, 1;129(22):3000-3008

PubMed: 28424165 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2103

PubMed: 29235459 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(9):2313-2324

PubMed: 27697994 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

Oncogene, 2017, 36(26):3651-3660

PubMed: 28192408 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Front Immunol, 2017, 8:1221

PubMed: 29033940 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2586-2597

PubMed: 28835384 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

J Antimicrob Chemother, 2017, 72(2):467-477

PubMed: 27999013 ( click the link to review the publication )

Int J Oncol, 2017,

PubMed: 28339079 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 85:149-158

PubMed: 28254430 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 91(Pt A):1-8

PubMed: 28834761 ( click the link to review the publication )

PLoS One, 2017, 12(3):e0172858

PubMed: 28257435 ( click the link to review the publication )

Am J Reprod Immunol, 2017, 78(4)

PubMed: 28635072 ( click the link to review the publication )

J Pharmacol Sci, 2017, 134(4):197-202

PubMed: 28779993 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(4):436-445

PubMed: 28125433 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28418900 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6102-6113

PubMed: 28008149 ( click the link to review the publication )

Oncotarget, 2017, 8(14):23213-23227

PubMed: 28390196 ( click the link to review the publication )
JCI Insight, 2017,

PubMed: 28422756 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29245981 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114924-114934

PubMed: 29383130 ( click the link to review the publication )

Oncotarget, 2017, 8(47):81794-81802

PubMed: 29137222 ( click the link to review the publication )

Oncotarget, 2017, 8(1):742-756

PubMed: 27888629 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(6):E980-E989

PubMed: 28049849 ( click the link to review the publication )

Blood, 2016, 127(25):3192-201

PubMed: 27095788 ( click the link to review the publication )

Blood, 2016, 128(4):574-83

PubMed: 27235137 ( click the link to review the publication )

Ann Oncol, 2016, 27(6):1123-8

PubMed: 26961147 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

Leukemia, 2016, 30(1):74-85

PubMed: 26220042 ( click the link to review the publication )

Leukemia, 2016, 30(2):337-45

PubMed: 26338274 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35(1):78

PubMed: 27176481 ( click the link to review the publication )

Pain, 2016, 157(1):137-46

PubMed: 26313408 ( click the link to review the publication )

Cancer Sci, 2016,

PubMed: 27348272 ( click the link to review the publication )

J Immunol, 2016, 197(7):2918-29

PubMed: 27559048 ( click the link to review the publication )

J Virol, 2016, 90(14):6443-52

PubMed: 27147739 ( click the link to review the publication )

Acta Pharmacol Sin, 2016, 37(10):1281-1297

PubMed: 27569389 ( click the link to review the publication )

Int J Oncol, 2016, 48(1):253-60

PubMed: 26549638 ( click the link to review the publication )

Oncol Rep, 2016, 36(6):3643-3650

PubMed: 27748929 ( click the link to review the publication )

Br J Pharmacol, 2016, 173(18):2726-38

PubMed: 27352269 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41031-41046

PubMed: 27127886 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27174919 ( click the link to review the publication )
Leukemia, 2016, 30(9):1963

PubMed: 27600169 ( click the link to review the publication )

Thromb Haemost, 2016, 115(6):1138-46

PubMed: 26818901 ( click the link to review the publication )

Oncotarget, 2016, 7(45):72608-72621

PubMed: 27579615 ( click the link to review the publication )

Blood, 2015, 126(11):1336-45

PubMed: 26162407 ( click the link to review the publication )

Blood, 2015, 10.1182/blood-2014-12-618470

PubMed: 25833959 ( click the link to review the publication )

Blood, 2015, 10.1182/blood-2014-11-610329

PubMed: 25957390 ( click the link to review the publication )

Nat Commun, 2015, 6:5937

PubMed: 25583025 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(52):E7230-8

PubMed: 26668357 ( click the link to review the publication )

Haematologica, 2015, 100(1):77-86

PubMed: 25344523 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.01.002

PubMed: 25660021 ( click the link to review the publication )

Haematologica, 2015,

PubMed: 25957396 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

Stem Cells, 2015, 10.1002/stem.1986

PubMed: 25753288 ( click the link to review the publication )

J Leukoc Biol, 2015, 98(6):1091-105

PubMed: 26265781 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137917

PubMed: 26360058 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2699-708

PubMed: 25964548 ( click the link to review the publication )

Cancer Biol Med, 2015, 12(4):401-8

PubMed: 26779377 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25999352 ( click the link to review the publication )

Blood, 2014, 123(2):239-50

PubMed: 24191150 ( click the link to review the publication )

Blood, 2014, 123(26):4120-31

PubMed: 24711662 ( click the link to review the publication )

J Clin Invest, 2014, 124(4):1794-809

PubMed: 24569456 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(6):1576-89

PubMed: 24634471 ( click the link to review the publication )

Cell Death Differ, 2014, 21(10):1535-45

PubMed: 24992930 ( click the link to review the publication )
Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Br J Haematol, 2014, 166(4):529-39

PubMed: 24766330 ( click the link to review the publication )

J Immunol, 2014, 192(5):2063-70

PubMed: 24470496 ( click the link to review the publication )

PLoS One, 2014, 9(6):e98818

PubMed: 24901342 ( click the link to review the publication )

Chem Biol, 2014, 21(8):955-66

PubMed: 25065531 ( click the link to review the publication )

Nature, 2014, 516(7530):254-8

PubMed: 25274307 ( click the link to review the publication )

Leukemia, 2013, 28(3):629-41

PubMed: 24263804 ( click the link to review the publication )

Leukemia, 2013, 27(10):2096-100

PubMed: 23545990 ( click the link to review the publication )

Leukemia, 2013, 27(10):2094-6

PubMed: 23900138 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e827

PubMed: 24091670 ( click the link to review the publication )

J Pharmacol Exp Ther, 2013, 347(3):669-80

PubMed: 24068833 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(9):1201-7

PubMed: 23892273 ( click the link to review the publication )

PLoS One, 2013, 8(2):e57809

PubMed: 23460911 ( click the link to review the publication )

PLoS One, 2013, 8(8):e69126

PubMed: 23936317 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

Blood, 2012, 120(19):3978-85

PubMed: 22927247 ( click the link to review the publication )

Am J Pathol, 2012, 180(5):1906-16

PubMed: 22433439 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40852

PubMed: 22808277 ( click the link to review the publication )

Eur J Cancer, 2011, 48(1):149-57

PubMed: 22079609 ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

特性

Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。

靶点

p110δ ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)
2.5 nM	89 nM

体外研究

CAL-101 对p110α, p110β,和p110γ作用效果不大。CAL-101作用于原代嗜碱细胞特定阻断FcϵR1 p110δ调节的 CD63表达，EC50 为8 nM。与急性髓性白血病(AML) 和骨髓增生性肿瘤(MPN) 细胞相比，CAL-101 作用于B-cell急性淋巴细胞白血病(B-ALL)和慢性淋巴细胞白血病(CLL) 细胞时显示更强的活性。CAL-101 作用于SU-DHL-5, KARPAS-422 和CCRF-SB细胞，降低pAktS473, pAktT308, 和下游靶点S6， EC50为0.1到1.0 μM。 ^[1] CAL-101 作用于CLL细胞，诱导选择性细胞毒性，不是通过突变状态或间期细胞遗传学,主要通过caspase依赖机制。与正常B细胞相比，CAL-101作用于CLL 细胞优先产生细胞毒性，和LY294002相比，作用于其他造血细胞不会产生毒性。CAL-101 作用于T 细胞和天然杀伤细胞缺乏直接的细胞毒性潜能。CAL-101抑制炎症细胞因子的产生,比如 IL-6, IL-10, TNF-α,和IFN-γ,且激活诱导的细胞因子,如CD40L。CAL-101 也抗CD40L调节的CLL细胞存活。^[2] CAL-101 作用于L1236和L591细胞, 诱导细胞在G1期积累，在S期下降，说明 CAL-101可以作为治疗霍杰金淋巴瘤(HL)的一种新策略。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MEC1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2TDUWROW09?	M2HRbGlEPTB;MkCuOEDPxE1?	NHXEUnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm5PVM2Oid-MkW5PVk{PTJ:L3G+
CLL PBMCs	NX;zcohuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEXycppFVVOR	M2nk[WlEPTB;Mj65JI5O	NHLv[5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO\|I3Pyd-MkW5NVczPjd:L3G+
U266	M3f0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjyb3A1OCEQvF2=	NI\Yb5c1QCCq		MlvoO\|kvPSViaX7obYJqfGmxbjDyZZRm	M{TwbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O5N\|MzLz5{NUOzPVM{OjxxYU6=
K562	MlP1SpVv[3Srb36gRZN{[Xl?	MYSxJO69VQ>?	MX[zJIg>		NYfrbpJYUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u	M4fRWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O\|c2Lz5{NUCxOFc4PTxxYU6=
K562	M1T5SWZ2dmO2aX;uJGF{e2G7	MYexJO69VQ>?	NWTDWXp6OyCq		MYHJcohq[mm2aX;uJI9nKFB5MGO2T{BxcG:\|cHjvdplt[XSrb36=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTBzNEe3OUc,OjVyMUS3O\|U9N2F-
K562	M1LvXmZ2dmO2aX;uJGF{e2G7	MmToNUDPxE1?	NVvQTWxXOyCq		NWjJVHhxUW6qaXLpeIlwdiCxZjDHV2s{KHCqb4PwbI9zgWyjdHnvci=>	M4fGN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O\|c2Lz5{NUCxOFc4PTxxYU6=
K562	Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;jUlA2OSEQvF2=	NIDYemc4OiCq		MYHJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36=	NFLje4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+
Primary AML cell	MmnxSpVv[3Srb36gRZN{[Xl?	NETSd4MyKM7:TR?=	M1zCWlMhcA>?		NHLpNJBKdmirYnn0bY9vKG:oIFHreEBxcG:\|cHjvdplt[XSrb36=	MkTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUS3O\|UoRjJ3MEG0O\|c2RC:jPh?=
Primary AML cell	NHT3e5dHfW6ldHnvckBCe3OjeR?=	MWOxJO69VQ>?	NEKzUIY{KGh?		MX;Jcohq[mm2aX;uJI9nKFB5MGO2T{BxcG:\|cHjvdplt[XSrb36=	M{G3[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O\|c2Lz5{NUCxOFc4PTxxYU6=
Primary AML cell	MWjGeY5kfGmxbjDBd5NigQ>?	M3PhU\|Eh\|ryP	MVyzJIg>		NV3IZZFKUW6qaXLpeIlwdiCxZjDHV2s{KHCqb4PwbI9zgWyjdHnvci=>	NWD3PGdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=>
Primary AML cell	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmniNUDPxE1?	MXOzJIg>		NEXqVHhUfXCycnXzd4lwdiCxZjDyVm5CKHO7boTo[ZNqew>?	NEK0W4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+
Microglia	M3TFdGZ2dmO2aX;uJGF{e2G7	M1nIU\|Uh\|ryP	NULjV3VSOTBiaB?=	MX;EUXNQ	M3[yW2Rm[3KnYYPlJI9nKFSQRnGgd4VkemW2aX;uJIZzd21iTGDTMZN1cW23bHH0[YQhKHBzMUFOuGQ6OTCDL1S5NVBCKG2rY4Lv[4xq[Q>?	NYLW[495RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlU3QDRpPkK0OlI2Pjh2PD;hQi=>
Primary CLL cell	MkTESpVv[3Srb36gRZN{[Xl?	M2XLflEh\|ryP	NH;OTFIyPSCvaX6=	MkPoSG1UVw>?	NE\RWpVDdG:la4OgRmNTNWmwZIXj[YQhVEOSMTDz[ZJqdmVvNTDhZ5RqfmG2aX;u	MmPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMEmyN\|MoRjJ2MEC5NlM{RC:jPh?=
JEKO-1	NWLxdJZbTnWwY4Tpc44hSXO\|YYm=	MUGxJO69VQ>?	NELJWlI4OiCq		MkfFTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJGloVS2\|dHnteYxifGWmIFrFT28uOQ>?	NGHDXo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O0NVU1OSd-MkOzOFE2PDF:L3G+
Granta-519	M4nLcmZ2dmO2aX;uJGF{e2G7	MonPNUDPxE1?	NET0VlYzKGh?		M3OwXmlvcGmkaYTpc44hd2ZiQXv0LJQ{ODhrIIDoc5NxcG:{eXzheIlwdg>?	M4\6bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{SxOVQyLz5{M{O0NVU1OTxxYU6=
Granta-519	NHvvZ4lHfW6ldHnvckBCe3OjeR?=	M1\0[\|Eh\|ryP	MlvpNkBp		NYjzbYhuUW6qaXLpeIlwdiCxZjDBb5QpezR5MzmgdIhwe3Cqb4L5cIF1cW:w	M{TjOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{SxOVQyLz5{M{O0NVU1OTxxYU6=
JEKO-1	M1jRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTsNVAh\|ryP	MXK3NkBp		NHX3ZW9KdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44he2yrZ3j0cJk>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN2MUW0NUc,OjN\|NEG1OFE9N2F-
JEKO-1	NFj0d5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYG1JO69VQ>?	NGDKenY4OiCq		M3K3TYRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW\|dDDvdkBieG:ydH;zbZM>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ5NkKyNEc,OjN4N{[yNlA9N2F-
MAVER-1	NGLBSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXBOUDPxE1?	NHzMdmg4OiCq		MmDq[I9meyCwb4SgbY5lfWOnIHPlcIwh[3mlbHWgZZJz\XO2IH;yJIFxd3C2b4Ppdy=>	NFriW2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3OlIzOCd-MkO2O\|YzOjB:L3G+
MINO	NEHYW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGO4NmE2KM7:TR?=	MWq3NkBp		M3WyeoRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW\|dDDvdkBieG:ydH;zbZM>	NYGxR\|J3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2O\|YzOjBpPkKzOlc3OjJyPD;hQi=>
SP53	M4DYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXkNE4yKM7:TR?=	MYq3NkBp		NGPjdFNld2W\|IH7veEBqdmS3Y3WgZ4VtdCCleXPs[UBienKnc4Sgc5Ih[XCxcITvd4l{	NWfGWVVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2O\|YzOjBpPkKzOlc3OjJyPD;hQi=>
HH	M1fXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV2xNEDPxE1?	NUm3R\|B5PzJiaB?=	NEW0TYFFVVOR	M4TwdGlv\HWldHnvckBw\iCjcH;weI9{cXNic3zp[4h1dHl?	NGjvOXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwNVk2QSd-MkK4NFE6PTl:L3G+
Myla	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\nd3ExOTBizszN	MVW3NkBp	M2PhU2ROW09?	MYnkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|	NF;PWJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwNVk2QSd-MkK4NFE6PTl:L3G+
SR786	Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnlNnUyOCEQvF2=	MVq3NkBp	NVPpcJZHTE2VTx?=	NIToWnVld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nz	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyMUm1PUc,OjJ6MEG5OVk9N2F-
HuT78	NFHSc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUOxNEDPxE1?	MW[3NkBp	MUjEUXNQ	NWHzVGpJ\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=>	MmDvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEG5OVkoRjJ{OECxPVU6RC:jPh?=
MJ	NGTSb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3K0WFExKM7:TR?=	MUG3NkBp	MlLqSG1UVw>?	MWXkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|	M1vmfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OECxPVU6Lz5{MkiwNVk2QTxxYU6=
DERL7	NHfle\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV[5NI1xOTBizszN	M1\icFczKGh?	NITxXFdFVVOR	NFjYN5Vld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nz	MmPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEG5OVkoRjJ{OECxPVU6RC:jPh?=
L1236	NIHoV4JHfW6ldHnvckBCe3OjeR?=	NFLuOWcyOCEQvF2=	NGGwZoUzKGh?		NV\JT2huUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O\|c9N2F-
L428	MWfGeY5kfGmxbjDBd5NigQ>?	MYqxNEDPxE1?	Ml\QNkBp		NV7pe3lGUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u	MnjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUC4O\|coRjJ{MkGwPFc4RC:jPh?=
L591	NF\Sbm9HfW6ldHnvckBCe3OjeR?=	M3fVbVExKM7:TR?=	NX\rUnN6OiCq		M{LaNmlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?=	NEnaZ\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+
KMH-2	M3nySmZ2dmO2aX;uJGF{e2G7	Ml3rNVAh\|ryP	NXuzcFY3OiCq		NILwe5pKdmirYnn0bY9vKG:oIFHreEBxcG:\|cHjvdplt[XSrb36=	M1vofFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGwPFc4Lz5{MkKxNFg4PzxxYU6=
L1236	M3i5RWZ2dmO2aX;uJGF{e2G7	NFnyR5M2KM7:TR?=	MWCyOEBp		MUHCcI9kc3Nic3XjdoV1cW:wIH;mJJRp\SCFQ1y1	NVryWZNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVA5PzdpPkKyNlExQDd5PD;hQi=>
L591	M2XNOmZ2dmO2aX;uJGF{e2G7	NFv4TXM2KM7:TR?=	MV2yOEBp		NFrjOI9DdG:la4Ogd4VkemW2aX;uJI9nKHSqZTDDR2w2	M3zoRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGwPFc4Lz5{MkKxNFg4PzxxYU6=
L1236	NFnVPHJCeG:ydH;zbZMhSXO\|YYm=	NEHVSlA2KM7:TR?=	NEK3ZXUzPCCq		M4\HO2lv\HWldHnvckBw\iCjcH;weI9{cXN?	NFjqSWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+
L591	NW\VWJg5SXCxcITvd4l{KEG\|c3H5	M4rmN\|Uh\|ryP	Mmf1NlQhcA>?		NELnT2FKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|	M4TK[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGwPFc4Lz5{MkKxNFg4PzxxYU6=
U-87MG	M1\6dmZ2dmO2aX;uJGF{e2G7	MWKxNFAhdk1?	NHnTWFUzPCCq	NHTaZnVFVVOR	MVfJcohq[mm2aX;uJI9nKCClZXzsJI1q\3KjdHnvci=>	M4jXfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEe5OlA6Lz5{MkC3PVYxQTxxYU6=
SW1783	M1ryRmZ2dmO2aX;uJGF{e2G7	MYixNFAhdk1?	MWCyOEBp	NWTIWIJ[TE2VTx?=	MofxTY5pcWKrdHnvckBw\iBiY3XscEBucWe{YYTpc44>	MlfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyN{m2NFkoRjJ{MEe5OlA6RC:jPh?=
U-87MG	NV3SVo5NTnWwY4Tpc44hSXO\|YYm=	NX;qXnFjPSEQvF2=	MX6yOEBp	NU[ySohPTE2VTx?=	M4jmbGlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDzeYJ{fGGwdHnhcIx6	NX3qU\|NXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO\|k3ODlpPkKyNFc6PjB7PD;hQi=>
SW1783	NULnR3A3TnWwY4Tpc44hSXO\|YYm=	Mm\WOUDPxE1?	MnnDNlQhcA>?	NH\rNYdFVVOR	M{XyNWlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDzeYJ{fGGwdHnhcIx6	Ml7RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyN{m2NFkoRjJ{MEe5OlA6RC:jPh?=
U-373MG	M1\WSWZ2dmO2aX;uJGF{e2G7	MlvHOUDPxE1?	NUXXZpMzOjRiaB?=	M2PSeWROW09?	NILHUVhKdmirYnn0bY9vKG:oIFHreEBxcG:\|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>?	MnzsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyN{m2NFkoRjJ{MEe5OlA6RC:jPh?=
SK-MG3	NH7iUJdHfW6ldHnvckBCe3OjeR?=	M{XZVVUh\|ryP	MVSyOEBp	MmX2SG1UVw>?	MnnYTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk>	NEC4WFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC3PVYxQSd-MkKwO\|k3ODl:L3G+
SU-DHL-5	NYG1blVGTnWwY4Tpc44hSXO\|YYm=	MkDyNUDPxE1?	NFLXcJYzPCCq	MlfCSG1UVw>?	NFnFcXVKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|	NGf3Z3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEm1PVYxPid-MkC5OVk3ODZ:L3G+
WSU-NHL	MmPaSpVv[3Srb36gRZN{[Xl?	M2jRXlEh\|ryP	Mlv3NlQhcA>?	M{fvU2ROW09?	NVq1enJsUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?=	MkXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7NUm2NFYoRjJyOUW5OlA3RC:jPh?=
CCRF-SB	NUTQVoV1TnWwY4Tpc44hSXO\|YYm=	NHnhfZUyKM7:TR?=	M4OzUFI1KGh?	NYnPdnBYTE2VTx?=	M1;hXmlv\HWldHnvckBw\iCjcH;weI9{cXN?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl3OU[wOkc,OjB7NUm2NFY9N2F-
INA-6	M13IR2Z2dmO2aX;uJGF{e2G7	M3u1OFUh\|ryP	M4SwT\|YhcA>?		NXfEeVJwUW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDhcoQhTVKNIIDheIh4[Xl?	NWGyWFl7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1NFUyPThpPkKwOVA2OTV6PD;hQi=>
LB	MkDQSpVv[3Srb36gRZN{[Xl?	MYm1JO69VQ>?	NF7GOHM3KGh?		NIDDdXJKdmirYnn0bY9vKG:oIGDJOGswSWu2IHHu[EBGWkticHH0bJdigQ>?	Mm\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3MEWxOVgoRjJyNUC1NVU5RC:jPh?=
B-cells	M4XMeGZ2dmO2aX;uJIF{e2G7				NXvuTINzUW6qaXLpeIlwdiCxZjDQTVNM\GWudHGgbY4hSi2lZXzsd{BjgSCycn;sbYZmemG2aX;uJIF{e2G7LDDJR\|UxKD1iMD6wNFYyKM7:TT6=	Mn\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7MkS2PFgoRjJ{OUK0Olg5RC:jPh?=
MOLM14	NWS2O29lSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NIfCRnQ{KGSjeYO=		NFPC[GNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFMvPiEQvF2u	M1W5fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6=
MV4-11	MnWyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MlrBN{Bl[Xm\|		MmjqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGlEPTBiPTC2MlMh\|ryPLh?=	NVz5WHJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOjdpPkK3O\|c1OTJ5PD;hQi=>
Jurkat	MnHORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MnK3N{Bl[Xm\|		MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEq3cnvheEBk\WyuczDh[pRmeiB\|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IEeuPUDPxE1w	Mn7TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5N{SxNlcoRjJ5N{e0NVI4RC:jPh?=
Loucy	M4i0N2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXmzJIRigXN?		NVy5dm5NSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMc5VkgSClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFgvPCEQvF2u	M3PZSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6=
MOLT4	Mki3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFLKNmI{KGSjeYO=		NGLnZ21CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUHQ1KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBKSzVyIE2gNVAvPiEQvF2u	NF6xOlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFEzPyd-Mke3O\|QyOjd:L3G+
insect cells	MkDFSpVv[3Srb36gZZN{[Xl?				NIraNJhKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJGhqey22YXfn[YQhWEl\|S3fhcY1iKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMtKEmFNUCgQUAxNjB6OTFOwG0v	MmW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6NE[0OVEoRjJ5OES2OFUyRC:jPh?=
SUDHL6	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWm3NkBpenN?		MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOXRFjMOkBk\WyuczDt[YF{fXKnZDDh[pRmeiB5MjDodpMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSByLkGxO\|Yh\|ryPLh?=	NVztXmxXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4OFY1PTFpPkK3PFQ3PDVzPD;hQi=>
insect cells	NIDRR4RHfW6ldHnvckBie3OjeR?=				NXHQeXhzUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBJcXNvdHHn[4VlKFCLM1vi[ZRiKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMtKEmFNUCgQUAxNjV4NTFOwG0v	NEjqZnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{i0OlQ2OSd-Mke4OFY1PTF:L3G+
SU-DHL4	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{PLdlczKGi{cx?=		MmW3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVVT3ETGw1KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEGuOkDPxE1w	Mo\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6NE[0OVEoRjJ5OES2OFUyRC:jPh?=
Pfeiffer	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUS3NkBpenN?		NHPK[GZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDm[Yln\mW{IHPlcIx{KG2nYYP1doVlKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFYvQCEQvF2u	M2fDblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OES2OFUyLz5{N{i0OlQ2OTxxYU6=
KARPAS422	NVzxUIY5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2XNTFczKGi{cx?=		M1TtfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1HSVGFUPDJ{IHPlcIx{KG2nYYP1doVlKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFgvOSEQvF2u	NXjpb4ZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4OFY1PTFpPkK3PFQ3PDVzPD;hQi=>
Sf21	NETrWJBHfW6ldHnvckBie3OjeR?=		Mn\oN\|AhdWmwcx?=		NFXtZ\|VKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhemWlb33ibY5idnRiZoXscE1t\W6pdHigbJVu[W5iUFmzT{BxOTFyYnX0ZU92dnSjZ3fl[EBz\WOxbXLpcoFvfCCodXzsJIxmdme2aDDoeY1idiCyOEXhcJBp[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z{MTDpcpNm[3RiY3XscJMhfXOrbnegVGlROi:DVGCgZZMhe3Wkc4TyZZRmKGGodHXyJFMxKG2rboOgZpkhXFJvRmLFWEBie3OjeTygTWM2OCB;IEOuO{DPxE1w	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDFyNkm5NUc,OjhzME[5PVE9N2F-
Sf21	MWLGeY5kfGmxbjDhd5NigQ>?		NWHxXIZ3OzBibXnudy=>		MVvJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzOk11[WepZXSgdoVkd22kaX7hcpQh\nWubD3s[Y5ofGhiaIXtZY4hWEl\|SzDwNVEx[mW2YT;1cpRi\2enZDDy[YNwdWKrbnHueEBnfWyuIHzlcod1cCCqdX3hckBxQDWjbIDoZUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4YzOSCrboPlZ5Qh[2WubIOgeZNqdmdiUFnQNk9CXFBiYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiYomgWHIuTlKHVDDhd5NigSxiSVO1NEA:KDNwNzFOwG0v	M3rYR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUC2PVkyLz5{OEGwOlk6OTxxYU6=
RPMI8266	NVvKWGhYSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmfLO\|IhcHK\|		M1TqU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmDNTVgzPjZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODB3NEmg{txONg>?	NI\DeVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOyOVYxOSd-MkizNlU3ODF:L3G+
Raji	NH;Kb3NCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MX23NkBpenN?		NYfFcoprSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSZYpqKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAxQTl3IN88UU4>	NYr4T4ZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNlU3ODFpPkK4N\|I2PjBzPD;hQi=>
KARPAS422	Mmm5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NYC3TJpDT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hU0GUUFHTOFIzKGOnbHzzJIJ6KEOFS{igZZN{[XluIFfJOVAhRSByLk[4JO69VS5?	NUDFNJV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N\|U5ODVpPkK4PFM2QDB3PD;hQi=>
Pfeiffer	M1n2dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NYKxfllsT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWG[naX\m[ZIh[2WubIOgZpkhS0ONODDhd5NigSxiR1m1NEA:KDBwN{Sg{txONg>?	M4T4TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEO1PFA2Lz5{OEizOVgxPTxxYU6=
Saos-2	NFjabWhyUFSVIHHzd4F6				M2PFWpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	M2LzZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	MnnWdWhVWyCjc4PhfS=>				MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	M3zWbJFJXFNiYYPzZZk>				NE\WSFlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO=	NVLEPVlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	NFvIXG5yUFSVIHHzd4F6				MUjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	M3\LR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	MVPxTHRUKGG\|c3H5				MoDZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	NFm5NGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NXnzTZhFeUiWUzDhd5NigQ>?				Mmq5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	M1K2NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NFn0R3ByUFSVIHHzd4F6				Ml;5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MkX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	M{\iR5FJXFNiYYPzZZk>				Mk[0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	NUXvUJZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	MkHhdWhVWyCjc4PhfS=>				M371e5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	MkfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SUDHL6	NF\sO2RCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2jrdlczKGi{cx?=		M2m2UmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2XETGw3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyIE2gNE43PSEQvF2u	M3z0ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVM3Lz5{OUWzOFk{PjxxYU6=
RPMI8226	NWfSdo1[SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVS0R25qPzJiaILz		Mlq1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCUUF3JPFIzPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gOU41QSEQvF2u	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|NEmzOkc,Ojl3M{S5N\|Y9N2F-
Raji	M4O3dWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mnn2O\|IhcHK\|		NFja[FJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLhbokh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEmuPVUh\|ryPLh?=	M1OwVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVM3Lz5{OUWzOFk{PjxxYU6=
SU-DHL6	NUX4bYU4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NX30SIRET3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW1VvRFjMOkBk\WyuczDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5yNEKg{txONg>?	MkHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4MEG5PVEoRjJ7NkCxPVkyRC:jPh?=
MOLM13	NWPZ[nk{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NU\xe\|JKPzJiaILz		MmLCS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUW9NVTF\|IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX70JIF{e2G7LDDHTVUxKD1iMT63JO69VS5?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB3M{eyNUc,OzByNUO3NlE9N2F-
MOLM14	NHTyS4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MW[3NkBpenN?		Ml7MS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUW9NVTF2IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX70JIF{e2G7LDDHTVUxKD1iNj60JO69VS5?	MkjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNUO3NlEoRjNyMEWzO\|IyRC:jPh?=
MOLM14	NIDseoRCdnSrdIXtc5Ih[XO\|YYm=	M1j1SVExOCCvZz;r[y=>	NV7rOmw4OTRiZHH5dy=>		MVHBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPT1zNNVQh[2WubIOgfIVvd2e{YX\0[YQhcW5iboWvcpUhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhOTByIH3nM4toNCCybzDh[I1qdmm\|dHXy[YQh\GGrbImgeoliKGejdnHn[UBld3OnZDDmc5IhOTRiZHH5d{BidmRibXXhd5Vz\WRiZHHpcJkh\HW{aX7nJINwdXCxdX7kJIRwe2mwZzDy[YxifGm4ZTD0c{Bkd262cn;s	NHLBN3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC1N\|czOSd-M{CwOVM4OjF:L3G+
MOLM14	MX;BcpRqfHWvb4KgZZN{[Xl?	M3rVfVExOCCvZz;r[y=>	NV\tcIExOTRiZHH5dy=>		M4X1RmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueU9vfSCvb4Xz[UBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZZBweHSxc3nzJIF1KDFyMDDt[{9s\yxicH:gZYRucW6rc4TldoVlKGSjaXz5JJZq[SCpYY\h[4Uh\G:\|ZXSg[o9zKDF2IHThfZMh[W6mIH3lZZN2emWmIHThbYx6KGS3cnnu[{Bkd22yb4Xu[EBld3OrbnegZpkhXFWQRVygZoF{\WRiYYPzZZk>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB3M{eyNUc,OzByNUO3NlE9N2F-
MOLM14	NFvyVJdCdnSrdIXtc5Ih[XO\|YYm=	M3j3b\|ExOCCvZz;r[y=>	M3;BUVE1KGSjeYO=		NYjl[FAxSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUW9NVTF2IHPlcIx{KHinbn;ndoFnfGWmIHnuJI52N263IH3veZNmKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhfHWvb4KgdJJwdGmoZYLheIlwdiBzMECgcYcwc2duIIDvJIFldWmwaYP0[ZJm\CCmYXnsfUB3cWFiZ3H2ZYdmKGSxc3XkJIZweiBzNDDkZZl{KGGwZDDt[YF{fXKnZDDkZYltgSCmdYLpcoch[2:vcH;1coQh\G:\|aX7nJIJ6KEurLU[3JIxi[mWubHnu[{Bj[XOnZDDpcY12dm:q	M1PUeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEWzO\|IyLz5\|MEC1N\|czOTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PUMA / p53 ; PubMed: 28008149 Oncotarget Parental and p53-KD HCT116 cells were treated with 10 μmol/L idelalisib for 24 hours. PUMA expression was analyzed by Western blotting. Bim / Bcl-xl / Bid / Mcl-1; PubMed: 28008149 Oncotarget HCT116 cells treated with 10 μmol/L idelalisib at indicated time point. The expression of indicated Bcl-2 family members was analyzed by Western blotting. p-p65; PubMed: 28008149 Oncotarget HCT116 cells were treated with 10 μmol/L idelalisib at indicated time point. p-p65 (S536) and p65 expression was analyzed by Western blotting. p-AKT / AKT; PubMed: 28008149 Oncotarget HCT116 cells were treated with 10 μmol/L idelalisib at indicated time point. Total AKT and p-AKT expression was analyzed Western blotting. Cleaved caspase 3 / Cleaved caspase 9; PubMed: 28008149 Oncotarget HepG2 cells were treated with 5μmol/L idelalisib at indicated time point. Cleaved-caspase 3 and 9 were analyzed by western blotting. Mcl-1 / Bcl-2 / Bid / Bcl-xl / Noxa / Bak / Bax ; PubMed: 30224718 Cell Death Dis HepG2 cells were treated with 5 μmol/L idelalisib at indicated time points. The expression of indicated Bcl-2 family members was analyzed by western blotting and normalized to β-actin. The data represent the mean ± SD of three independent experiments. P < 0.01 (one-way ANOVA with Tukey’s post hoc test). p-FoxO3a / FoxO3a; PubMed: 30224718 Cell Death Dis HepG2 cells were treated with 5 μmol/L idelalisib for 24 h. Indicated protein expression was analyzed by western blotting and p-FoxO3a normalized to FoxO3a, p-AKT normalized to AKT. The data represent the mean ± SD of three independent experiments. P < 0.01 (one-way ANOVA with Tukey’s post hoc test). Akt(T308) / PDK1(S241) / GSK-3β(S9); PubMed: 27342398 Clin Cancer Res JeKo-1, Mino, and Granta 519 cells or cells from four different MCL patients were serum-starved for 1h and then treated with DMSO, or with 0.5, 1, or 3μM for 1h; the cells were then co-cultured with IgM (10ng/μL) for 15min before harvesting. Cell extracts were prepared, and 30μg (cell lines) or 50μg (primary cells) protein was loaded for immunoblot analyses. The effects of idelalisib on Akt (Thr308) and total Akt, PDK1 (Ser241) and total PDK1, GS3K-3β (Ser9) and total GSK-3β protein expression levels were detected in (A) JeKo-1, Mino and Granta 519 cells.	28008149 30224718 27342398
Growth inhibition assay	Cell viability; PubMed: 28008149 Oncotarget Indicated cell lines were treated with different concentrations of idelalisib for 72 hours. Cell proliferation was determined by MTS assay. Results were expressed as means ± SD of three independent experiments. Cell viability; PubMed: 30224718 Cell Death Dis The indicated cell lines were treated with increasing concentrations of idelalisib for 72 h. Cell viability was determined by MTS assay.	28008149 30224718

激酶实验：^[2]	- 合并 PI3K实验: 用全CLL和正常B细胞溶解物进行PI3K实验。进行PI3K ELISA 实验。全细胞抽提物加到PI(4,5)P2 底物和反应 buffer（包含 ATP)的混合物中，在室温下温育。加入 PI(3,4,5)P3 探测器和 EDTA混合，反应终止，在室温下温育1小时。混合物转移到PI3K ELISA板上，再温育1小时。冲洗反应板，然后和第二探测器再温育30分钟。再次冲洗反应板, 加入3,3′,5,5′-四甲基联苯胺溶液，反应5分钟，加入H₂SO₄ 终止反应。在450纳米处读数。
细胞实验：^[2]	- 合并 Cell lines: CLL B 细胞或健康志愿者的T细胞或NK细胞 Concentrations: 0.01-100 μM Incubation Time: 48小时 Method: 进行MTT实验测定细胞毒性。1×10⁵个细胞和CAL-101一起温育。加入MTT试剂, 再次温育20小时，然后用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO, 用分光光度计在540纳米处测定吸光度。使用膜联蛋白/PI液式细胞计检查在不同时间点测定细胞存活力，分析数据。每个样本至少计数10⁴个细胞。以全部阳性细胞与未处理细胞之比百分数的形式来表示实验结果。加入100 μM Z-VAD检测caspase-依赖的细胞凋亡。加入 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α测定存活信号, 或者共培养在纤连蛋白或 HS-5 细胞系基质包被的板上。基质共培养在75cm²培养瓶 (80%-100% 融合率) 培养24 小时，然后加入CLL细胞。 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	83 mg/mL warmed (199.79 mM)
	Ethanol	23 mg/mL (55.36 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+20%PEG 300+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Idelalisib (CAL-101, GS-1101) SDF

分子量	415.42
化学式	C₂₂H₁₈FN₇O
CAS号	870281-82-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03582098	Completed	Drug: Idelalisib\|Drug: Rituximab	Chronic Lymphocytic Leukaemia	Gilead Sciences	September 12 2018	--
NCT03151057	Active not recruiting	Drug: Idelalisib 100 MG\|Drug: Placebo Oral Tablet	B Cells-Tumors\|B Cell Chronic Lymphocytic Leukemia\|Follicular Lymphoma\|Mantle Cell Lymphoma\|Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Gilead Sciences	July 31 2018	Phase 1
NCT03568929	Recruiting	Drug: Idelalisib	Follicular Non-Hodgkin''s Lymphoma Refractory	Gilead Sciences	May 25 2018	--

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What is the recommended dose of CAL-101 and the route of administration for mouse studies?
回答：
According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

泛PI3K抑制剂

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
活性最高的PI3K抑制剂

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
用于临床的PI3K抑制剂

Hexestrol : Phase II for Advanced Breast Cancer.
最新的PI3K抑制剂

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

研究领域

产品类型

定制您的化合物库

Idelalisib (CAL-101, GS-1101)

客户使用Selleck生产的Idelalisib (CAL-101, GS-1101)发表文献187篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Idelalisib (CAL-101, GS-1101) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技术支持

常见问题及建议解决方法

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品